相关实验视频

Updated: Sep 15, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

进展性多发性硬化症的生物标志物在自身造血干细胞移植后减少

Ida Erngren¹, Katarina Lundblad², Ivan Pavlovic²

¹Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.

Journal of neuroinflammation

|July 17, 2025

概括

自主造血干细胞移植 (AHSCT) 显著降低了与渐进性多发性硬化症 (MS) 相关的生物标志物. 这表明AHSCT可能会延迟或预防复发性复发性多发性硬化症 (RRMS) 患者的MS进展.

科学领域:

神经免疫学神经免疫学
干细胞移植干细胞移植
生物标志物发现发现

背景情况:

自主造血干细胞移植 (AHSCT) 是复发性复发性多发性硬化症 (RRMS) 的新兴治疗方法.
有证据表明,AHSCT可能会改变多发性硬化症的进展,可能会延迟或防止疾病的进展形式的出现.
本研究研究了AHSCT对与MS进展相关的脑脊液 (CSF) 特定生物标志物的影响.

研究的目的:

为了评估AHSCT对RRMS患者中CSF水平的Galectin-9,GDF-15和YKL-40的影响.
为了确定这些可预示MS进展的生物标志物是否会因AHSCT治疗而改变.
评估AHSCT在改变多发性硬化症疾病过程中的潜力.

主要方法:

从45名RRMS患者在AHSCT之前和之后 (1年和2年),以及32名健康对照的样本中收集了CSF样本.
使用ELISA测量了加勒-9和GDF-15度.
通过使用电化学发光来量化YKL-40水平.

主要成果:

与对照人群相比,在RRMS患者中,基线CSF水平的加列-9 ,YKL-40和GDF-15在RRMS患者中升高.
在AHSCT之后,所有三种生物标志物在1年的随访中都显示出显著的减少.
在2年的随访期间,Galectin-9和YKL-40的进一步下降被观察到,随后的水平保持稳定.

结论:

AHSCT治疗与与MS进展相关的CSF生物标志物的持续减少有关.
这些发现表明,AHSCT可能在延迟或预防向二次进展性MS (SPMS) 过渡方面提供治疗益处.
需要进一步的研究来证实这些结果,并了解它们的长期临床影响.

关键词:

自主造血干细胞移植自主造血干细胞移植生物标志物生物标志物在CSF的CSF中,这是GDF-15的GDF-15.盖尔-9是指加尔的9.多发性硬化症是多发性硬化症.在YKL-40中,YKL-40是最重要的.

更多相关视频

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...